NO330143B1 - Morfolinderivater, preparat inneholdende slike, slike forbindelser for anvendelse som medikament samt anvendelse av slike for fremstilling av medikament for behandling av sykdom - Google Patents

Info

Publication number

NO330143B1

NO330143B1 NO20052557A NO20052557A NO330143B1 NO 330143 B1 NO330143 B1 NO 330143B1 NO 20052557 A NO20052557 A NO 20052557A NO 20052557 A NO20052557 A NO 20052557A NO 330143 B1 NO330143 B1 NO 330143B1

Authority

NO

Norway

Prior art keywords

disorder

formula

compounds

depression

compound

Prior art date

2002-12-10

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 238
• 238000011282 treatment Methods 0.000 title claims abstract description 34
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 29
• 239000003814 drug Substances 0.000 title claims description 28
• 238000002360 preparation method Methods 0.000 title claims description 21
• 238000004519 manufacturing process Methods 0.000 title description 6
• 201000010099 disease Diseases 0.000 title description 4
• 150000002780 morpholines Chemical class 0.000 title 1
• 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 17
• 150000003839 salts Chemical class 0.000 claims abstract description 17
• 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
• 229910052727 yttrium Inorganic materials 0.000 claims abstract description 9
• 201000001880 Sexual dysfunction Diseases 0.000 claims abstract description 8
• 231100000872 sexual dysfunction Toxicity 0.000 claims abstract description 8
• 229910052799 carbon Inorganic materials 0.000 claims abstract description 4
• 239000012453 solvate Substances 0.000 claims abstract description 4
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
• 208000035475 disorder Diseases 0.000 claims description 25
• 230000001568 sexual effect Effects 0.000 claims description 22
• 206010057671 Female sexual dysfunction Diseases 0.000 claims description 21
• 201000001881 impotence Diseases 0.000 claims description 20
• 208000021663 Female sexual arousal disease Diseases 0.000 claims description 16
• 208000010228 Erectile Dysfunction Diseases 0.000 claims description 15
• 229940079593 drug Drugs 0.000 claims description 13
• 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims description 11
• 208000020016 psychiatric disease Diseases 0.000 claims description 11
• 230000004770 neurodegeneration Effects 0.000 claims description 9
• NHTSBJAUMOIPAS-ZOWNYOTGSA-N 3-[(2r)-4-propylmorpholin-2-yl]phenol;hydrochloride Chemical compound Cl.C1N(CCC)CCO[C@@H]1C1=CC=CC(O)=C1 NHTSBJAUMOIPAS-ZOWNYOTGSA-N 0.000 claims description 8
• 125000000217 alkyl group Chemical group 0.000 claims description 8
• 230000035946 sexual desire Effects 0.000 claims description 8
• GGNXXNYKGWVORA-ZDUSSCGKSA-N 2-fluoro-5-[(2r)-4-propylmorpholin-2-yl]phenol Chemical compound C1N(CCC)CCO[C@@H]1C1=CC=C(F)C(O)=C1 GGNXXNYKGWVORA-ZDUSSCGKSA-N 0.000 claims description 7
• 206010011953 Decreased activity Diseases 0.000 claims description 7
• 208000002193 Pain Diseases 0.000 claims description 7
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
• WYEGTIGJSHGEID-ZDUSSCGKSA-N pf-219,061 Chemical compound C1N(CCC)CCO[C@@H]1C1=CC=CC(O)=C1 WYEGTIGJSHGEID-ZDUSSCGKSA-N 0.000 claims description 7
• 206010012289 Dementia Diseases 0.000 claims description 6
• 206010012335 Dependence Diseases 0.000 claims description 6
• 208000018737 Parkinson disease Diseases 0.000 claims description 6
• 208000027520 Somatoform disease Diseases 0.000 claims description 6
• 230000007000 age related cognitive decline Effects 0.000 claims description 6
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
• 208000027753 pain disease Diseases 0.000 claims description 6
• 239000000126 substance Substances 0.000 claims description 6
• 208000011580 syndromic disease Diseases 0.000 claims description 6
• 208000031424 hyperprolactinemia Diseases 0.000 claims description 5
• 208000024309 orgasm disease Diseases 0.000 claims description 5
• DFTCYTDJDXZFSK-JQWIXIFHSA-N pf-592,379 Chemical compound O1C[C@H](C)N(CCC)C[C@H]1C1=CC=C(N)N=C1 DFTCYTDJDXZFSK-JQWIXIFHSA-N 0.000 claims description 5
• 210000005166 vasculature Anatomy 0.000 claims description 5
• 208000017701 Endocrine disease Diseases 0.000 claims description 4
• 206010020772 Hypertension Diseases 0.000 claims description 4
• 208000008589 Obesity Diseases 0.000 claims description 4
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
• 208000027089 Parkinsonian disease Diseases 0.000 claims description 4
• 206010034010 Parkinsonism Diseases 0.000 claims description 4
• 201000009916 Postpartum depression Diseases 0.000 claims description 4
• 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 4
• 206010047163 Vasospasm Diseases 0.000 claims description 4
• 230000002490 cerebral effect Effects 0.000 claims description 4
• 239000003085 diluting agent Substances 0.000 claims description 4
• 235000020824 obesity Nutrition 0.000 claims description 4
• 208000019899 phobic disease Diseases 0.000 claims description 4
• 206010036596 premature ejaculation Diseases 0.000 claims description 4
• 230000000306 recurrent effect Effects 0.000 claims description 4
• 208000022170 stress incontinence Diseases 0.000 claims description 4
• 208000024891 symptom Diseases 0.000 claims description 4
• 208000002271 trichotillomania Diseases 0.000 claims description 4
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
• 206010054196 Affect lability Diseases 0.000 claims description 3
• 208000008811 Agoraphobia Diseases 0.000 claims description 3
• 208000024827 Alzheimer disease Diseases 0.000 claims description 3
• 206010002650 Anorexia nervosa and bulimia Diseases 0.000 claims description 3
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
• 208000001573 Cataplexy Diseases 0.000 claims description 3
• 206010008025 Cerebellar ataxia Diseases 0.000 claims description 3
• 208000006561 Cluster Headache Diseases 0.000 claims description 3
• 206010011469 Crying Diseases 0.000 claims description 3
• 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 3
• 208000030814 Eating disease Diseases 0.000 claims description 3
• 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
• 208000001640 Fibromyalgia Diseases 0.000 claims description 3
• 206010019233 Headaches Diseases 0.000 claims description 3
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 3
• 208000026139 Memory disease Diseases 0.000 claims description 3
• 208000019695 Migraine disease Diseases 0.000 claims description 3
• 206010028980 Neoplasm Diseases 0.000 claims description 3
• 206010034912 Phobia Diseases 0.000 claims description 3
• 206010036618 Premenstrual syndrome Diseases 0.000 claims description 3
• 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 3
• 208000000323 Tourette Syndrome Diseases 0.000 claims description 3
• 208000016620 Tourette disease Diseases 0.000 claims description 3
• 208000022804 avoidant personality disease Diseases 0.000 claims description 3
• 229940049706 benzodiazepine Drugs 0.000 claims description 3
• 150000001557 benzodiazepines Chemical class 0.000 claims description 3
• 201000011510 cancer Diseases 0.000 claims description 3
• 230000001684 chronic effect Effects 0.000 claims description 3
• 229960003920 cocaine Drugs 0.000 claims description 3
• 229960002069 diamorphine Drugs 0.000 claims description 3
• 235000014632 disordered eating Nutrition 0.000 claims description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
• 231100000869 headache Toxicity 0.000 claims description 3
• 208000021267 infertility disease Diseases 0.000 claims description 3
• 206010023461 kleptomania Diseases 0.000 claims description 3
• 208000024714 major depressive disease Diseases 0.000 claims description 3
• 230000004899 motility Effects 0.000 claims description 3
• 239000003176 neuroleptic agent Substances 0.000 claims description 3
• 230000000701 neuroleptic effect Effects 0.000 claims description 3
• 229960002715 nicotine Drugs 0.000 claims description 3
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
• 208000019906 panic disease Diseases 0.000 claims description 3
• 230000001575 pathological effect Effects 0.000 claims description 3
• 208000022821 personality disease Diseases 0.000 claims description 3
• DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 3
• 229960002695 phenobarbital Drugs 0.000 claims description 3
• 201000000980 schizophrenia Diseases 0.000 claims description 3
• 230000028327 secretion Effects 0.000 claims description 3
• 230000035939 shock Effects 0.000 claims description 3
• 208000019116 sleep disease Diseases 0.000 claims description 3
• 208000020685 sleep-wake disease Diseases 0.000 claims description 3
• 201000001716 specific phobia Diseases 0.000 claims description 3
• 230000035882 stress Effects 0.000 claims description 3
• 208000019553 vascular disease Diseases 0.000 claims description 3
• 208000011688 Generalised anxiety disease Diseases 0.000 claims description 2
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
• 208000029364 generalized anxiety disease Diseases 0.000 claims description 2
• 208000010125 myocardial infarction Diseases 0.000 claims description 2
• YCIMNLLNPGFGHC-UHFFFAOYSA-N o-dihydroxy-benzene Natural products OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 2
• GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 2
• 229960001755 resorcinol Drugs 0.000 claims description 2
• CHAXZAKOMAQMHM-VAZZWQITSA-N C[C@H]1CO[C@H](CN1CCC)C=1C=CC(=NC1)N.ClC1=C(C=C(C=C1)C1CN(CCO1)CCC)O.C(CC)N1CC(OCC1)C=1C=CC(=NC1)N Chemical compound C[C@H]1CO[C@H](CN1CCC)C=1C=CC(=NC1)N.ClC1=C(C=C(C=C1)C1CN(CCO1)CCC)O.C(CC)N1CC(OCC1)C=1C=CC(=NC1)N CHAXZAKOMAQMHM-VAZZWQITSA-N 0.000 claims 1
• 230000003109 amnesic effect Effects 0.000 claims 1
• 230000001314 paroxysmal effect Effects 0.000 claims 1
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 6
• 229940052760 dopamine agonists Drugs 0.000 abstract description 2
• 239000003136 dopamine receptor stimulating agent Substances 0.000 abstract description 2
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
• 229940002612 prodrug Drugs 0.000 abstract 1
• 239000000651 prodrug Substances 0.000 abstract 1
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 208
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 144
• 210000004027 cell Anatomy 0.000 description 105
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 94
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 88
• 239000011541 reaction mixture Substances 0.000 description 84
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 83
• 238000005481 NMR spectroscopy Methods 0.000 description 76
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 53
• 239000000203 mixture Substances 0.000 description 52
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 51
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 51
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 45
• 238000000034 method Methods 0.000 description 45
• 239000003921 oil Substances 0.000 description 45
• 235000019198 oils Nutrition 0.000 description 45
• 229910001868 water Inorganic materials 0.000 description 44
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
• 238000007792 addition Methods 0.000 description 40
• OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 36
• 229960003089 pramipexole Drugs 0.000 description 36
• FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 36
• 239000000243 solution Substances 0.000 description 34
• 235000019439 ethyl acetate Nutrition 0.000 description 33
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
• -1 lithium aluminum hydride Chemical compound 0.000 description 32
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 30
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 29
• 239000010410 layer Substances 0.000 description 29
• HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 29
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 28
• 239000002953 phosphate buffered saline Substances 0.000 description 28
• 238000010992 reflux Methods 0.000 description 28
• 239000000377 silicon dioxide Substances 0.000 description 26
• 239000007787 solid Substances 0.000 description 25
• 239000000556 agonist Substances 0.000 description 24
• 238000004440 column chromatography Methods 0.000 description 24
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 24
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 24
• 238000012360 testing method Methods 0.000 description 24
• 239000012895 dilution Substances 0.000 description 23
• 239000012044 organic layer Substances 0.000 description 23
• 239000000047 product Substances 0.000 description 23
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 22
• 238000006243 chemical reaction Methods 0.000 description 22
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 21
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 21
• 238000010790 dilution Methods 0.000 description 21
• 239000000284 extract Substances 0.000 description 20
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 19
• SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 18
• OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 18
• 238000004458 analytical method Methods 0.000 description 17
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
• 150000001408 amides Chemical class 0.000 description 15
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
• 150000001412 amines Chemical class 0.000 description 14
• UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 14
• 239000012230 colorless oil Substances 0.000 description 14
• 229960004132 diethyl ether Drugs 0.000 description 14
• 239000000463 material Substances 0.000 description 14
• 239000002904 solvent Substances 0.000 description 14
• 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 13
• 238000003556 assay Methods 0.000 description 13
• 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 13
• 238000000746 purification Methods 0.000 description 13
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
• 230000037007 arousal Effects 0.000 description 12
• 239000000872 buffer Substances 0.000 description 12
• 210000004392 genitalia Anatomy 0.000 description 12
• 230000004044 response Effects 0.000 description 12
• 238000003756 stirring Methods 0.000 description 12
• 239000012298 atmosphere Substances 0.000 description 11
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical class NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 11
• 230000000694 effects Effects 0.000 description 11
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
• 238000001816 cooling Methods 0.000 description 10
• 239000012043 crude product Substances 0.000 description 10
• 238000010511 deprotection reaction Methods 0.000 description 10
• 230000001965 increasing effect Effects 0.000 description 10
• VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 10
• 229910000027 potassium carbonate Inorganic materials 0.000 description 10
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 9
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 9
• 239000002253 acid Substances 0.000 description 9
• 238000002474 experimental method Methods 0.000 description 9
• 239000003112 inhibitor Substances 0.000 description 9
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
• 230000000638 stimulation Effects 0.000 description 9
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 8
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 8
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
• 229910021529 ammonia Inorganic materials 0.000 description 8
• 125000006239 protecting group Chemical group 0.000 description 8
• WAJNANMQOPCIPO-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-7-one Chemical class O=C1N=CN=C2C=NN=C12 WAJNANMQOPCIPO-UHFFFAOYSA-N 0.000 description 8
• 102000005962 receptors Human genes 0.000 description 8
• 108020003175 receptors Proteins 0.000 description 8
• 238000013207 serial dilution Methods 0.000 description 8
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
• 230000004913 activation Effects 0.000 description 7
• 150000001414 amino alcohols Chemical class 0.000 description 7
• 229910000085 borane Inorganic materials 0.000 description 7
• UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 7
• 239000000470 constituent Substances 0.000 description 7
• ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 7
• 230000002265 prevention Effects 0.000 description 7
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
• ODPCIOYTCBXSOI-UHFFFAOYSA-N 2-chloro-5-(4-propylmorpholin-2-yl)phenol Chemical compound C1N(CCC)CCOC1C1=CC=C(Cl)C(O)=C1 ODPCIOYTCBXSOI-UHFFFAOYSA-N 0.000 description 6
• VZDVSSOINOOOOJ-ZDUSSCGKSA-N 5-[(2r)-4-propylmorpholin-2-yl]benzene-1,3-diol Chemical compound C1N(CCC)CCO[C@@H]1C1=CC(O)=CC(O)=C1 VZDVSSOINOOOOJ-ZDUSSCGKSA-N 0.000 description 6
• 229920000858 Cyclodextrin Polymers 0.000 description 6
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
• WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 6
• 239000000935 antidepressant agent Substances 0.000 description 6
• 239000006285 cell suspension Substances 0.000 description 6
• 150000002009 diols Chemical class 0.000 description 6
• 238000001704 evaporation Methods 0.000 description 6
• 230000008020 evaporation Effects 0.000 description 6
• 238000003306 harvesting Methods 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 239000012280 lithium aluminium hydride Substances 0.000 description 6
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
• 235000019341 magnesium sulphate Nutrition 0.000 description 6
• 238000010606 normalization Methods 0.000 description 6
• 239000012071 phase Substances 0.000 description 6
• 210000002460 smooth muscle Anatomy 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
• AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 6
• XDZBSCCFURVQOD-UHFFFAOYSA-N 2-bromo-4-(4-propylmorpholin-2-yl)phenol Chemical compound C1N(CCC)CCOC1C1=CC=C(O)C(Br)=C1 XDZBSCCFURVQOD-UHFFFAOYSA-N 0.000 description 5
• DFTCYTDJDXZFSK-CMPLNLGQSA-N 5-[(2s,5s)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine Chemical compound O1C[C@H](C)N(CCC)C[C@@H]1C1=CC=C(N)N=C1 DFTCYTDJDXZFSK-CMPLNLGQSA-N 0.000 description 5
• 208000019901 Anxiety disease Diseases 0.000 description 5
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
• VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 5
• 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 5
• 108090000525 Dopamine D3 Receptors Proteins 0.000 description 5
• 102000004073 Dopamine D3 Receptors Human genes 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 5
• 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 5
• 230000017531 blood circulation Effects 0.000 description 5
• 239000012267 brine Substances 0.000 description 5
• 239000011575 calcium Substances 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 229960003638 dopamine Drugs 0.000 description 5
• 229940011871 estrogen Drugs 0.000 description 5
• 239000000262 estrogen Substances 0.000 description 5
• 238000000605 extraction Methods 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 238000004128 high performance liquid chromatography Methods 0.000 description 5
• 238000005461 lubrication Methods 0.000 description 5
• 230000014759 maintenance of location Effects 0.000 description 5
• 150000002924 oxiranes Chemical class 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• 229920006395 saturated elastomer Polymers 0.000 description 5
• 208000012201 sexual and gender identity disease Diseases 0.000 description 5
• 208000015891 sexual disease Diseases 0.000 description 5
• BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 4
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
• HZWYVVALALXEJB-UHFFFAOYSA-N 2-amino-4-(4-propylmorpholin-2-yl)phenol Chemical compound C1N(CCC)CCOC1C1=CC=C(O)C(N)=C1 HZWYVVALALXEJB-UHFFFAOYSA-N 0.000 description 4
• KOVNCVPOPFUEPN-UHFFFAOYSA-N 2-hydroxy-5-(4-propylmorpholin-2-yl)benzamide Chemical compound C1N(CCC)CCOC1C1=CC=C(O)C(C(N)=O)=C1 KOVNCVPOPFUEPN-UHFFFAOYSA-N 0.000 description 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
• 101710095468 Cyclase Proteins 0.000 description 4
• 208000020401 Depressive disease Diseases 0.000 description 4
• 108090001111 Dopamine D2 Receptors Proteins 0.000 description 4
• 102000004980 Dopamine D2 Receptors Human genes 0.000 description 4
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 4
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 4
• NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
• 229910004298 SiO 2 Inorganic materials 0.000 description 4
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 4
• 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 4
• RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
• 239000005557 antagonist Substances 0.000 description 4
• 230000001430 anti-depressive effect Effects 0.000 description 4
• 229940005513 antidepressants Drugs 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 239000003638 chemical reducing agent Substances 0.000 description 4
• 238000001514 detection method Methods 0.000 description 4
• 206010012601 diabetes mellitus Diseases 0.000 description 4
• 238000010494 dissociation reaction Methods 0.000 description 4
• 230000005593 dissociations Effects 0.000 description 4
• 239000012153 distilled water Substances 0.000 description 4
• QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 4
• 230000007717 exclusion Effects 0.000 description 4
• 238000003818 flash chromatography Methods 0.000 description 4
• 239000007789 gas Substances 0.000 description 4
• 239000001963 growth medium Substances 0.000 description 4
• 238000002657 hormone replacement therapy Methods 0.000 description 4
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
• 208000014674 injury Diseases 0.000 description 4
• 239000008101 lactose Substances 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 description 4
• 230000018052 penile erection Effects 0.000 description 4
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
• 150000003180 prostaglandins Chemical class 0.000 description 4
• 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 4
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 4
• 235000017557 sodium bicarbonate Nutrition 0.000 description 4
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• 239000008107 starch Substances 0.000 description 4
• 229940032147 starch Drugs 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 229960003604 testosterone Drugs 0.000 description 4
• 238000010257 thawing Methods 0.000 description 4
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
• 230000002792 vascular Effects 0.000 description 4
• JEQDSBVHLKBEIZ-REOHCLBHSA-N (2s)-2-chloropropanoyl chloride Chemical compound C[C@H](Cl)C(Cl)=O JEQDSBVHLKBEIZ-REOHCLBHSA-N 0.000 description 3
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
• KVQJVAOMYWTLEO-UHFFFAOYSA-N 2-chlorobutanoyl chloride Chemical compound CCC(Cl)C(Cl)=O KVQJVAOMYWTLEO-UHFFFAOYSA-N 0.000 description 3
• WOLAYLBKITVXRB-ZSOXZCCMSA-N 3-[(5s)-5-methyl-4-propylmorpholin-2-yl]phenol Chemical compound O1C[C@H](C)N(CCC)CC1C1=CC=CC(O)=C1 WOLAYLBKITVXRB-ZSOXZCCMSA-N 0.000 description 3
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
• OURXRFYZEOUCRM-UHFFFAOYSA-N 4-hydroxymorpholine Chemical compound ON1CCOCC1 OURXRFYZEOUCRM-UHFFFAOYSA-N 0.000 description 3
• MCVFILRDWPXYCN-UHFFFAOYSA-N 5-(4-propylmorpholin-2-yl)pyridin-2-amine Chemical compound C1N(CCC)CCOC1C1=CC=C(N)N=C1 MCVFILRDWPXYCN-UHFFFAOYSA-N 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
• 206010009094 Chronic paroxysmal hemicrania Diseases 0.000 description 3
• 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 3
• 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 3
• 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
• 229930064664 L-arginine Natural products 0.000 description 3
• 235000014852 L-arginine Nutrition 0.000 description 3
• 206010024419 Libido decreased Diseases 0.000 description 3
• 206010057672 Male sexual dysfunction Diseases 0.000 description 3
• 102100024197 Membrane metallo-endopeptidase-like 1 Human genes 0.000 description 3
• GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 3
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
• 235000019502 Orange oil Nutrition 0.000 description 3
• XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 3
• 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 3
• ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 description 3
• SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 3
• 239000000654 additive Substances 0.000 description 3
• 102000030621 adenylate cyclase Human genes 0.000 description 3
• 108060000200 adenylate cyclase Proteins 0.000 description 3
• 230000036506 anxiety Effects 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 210000003029 clitoris Anatomy 0.000 description 3
• 210000005226 corpus cavernosum Anatomy 0.000 description 3
• MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 3
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
• 229960002986 dinoprostone Drugs 0.000 description 3
• 238000003821 enantio-separation Methods 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 238000013100 final test Methods 0.000 description 3
• 238000005984 hydrogenation reaction Methods 0.000 description 3
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
• 208000017020 hypoactive sexual desire disease Diseases 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 230000002197 limbic effect Effects 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 3
• 230000008018 melting Effects 0.000 description 3
• 238000002844 melting Methods 0.000 description 3
• 230000009245 menopause Effects 0.000 description 3
• 239000002858 neurotransmitter agent Substances 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 239000010502 orange oil Substances 0.000 description 3
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
• XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 3
• 229960001723 oxytocin Drugs 0.000 description 3
• 208000007777 paroxysmal Hemicrania Diseases 0.000 description 3
• 235000019271 petrolatum Nutrition 0.000 description 3
• LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 3
• 230000001817 pituitary effect Effects 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 3
• GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 3
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
• 229940075993 receptor modulator Drugs 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 238000006722 reduction reaction Methods 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 230000009329 sexual behaviour Effects 0.000 description 3
• 239000012279 sodium borohydride Substances 0.000 description 3
• 229910000033 sodium borohydride Inorganic materials 0.000 description 3
• 239000007921 spray Substances 0.000 description 3
• 230000008961 swelling Effects 0.000 description 3
• WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
• FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 3
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
• YKWCXUFYMYCVCS-RGMNGODLSA-N (2s)-2-(propylamino)propan-1-ol;hydrochloride Chemical compound Cl.CCCN[C@@H](C)CO YKWCXUFYMYCVCS-RGMNGODLSA-N 0.000 description 2
• JDKLPDJLXHXHNV-MFVUMRCOSA-N (3s,6s,9r,12s,15s,23s)-15-[[(2s)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1h-imidazol-5-ylmethyl)-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide Chemical compound C([C@@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCNC(=O)C[C@@H](C(N[C@@H](CC=2NC=NC=2)C(=O)N1)=O)NC(=O)[C@@H](NC(C)=O)CCCC)C(N)=O)C1=CC=CC=C1 JDKLPDJLXHXHNV-MFVUMRCOSA-N 0.000 description 2
• GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
• IVVNZDGDKPTYHK-JTQLQIEISA-N 1-cyano-2-[(2s)-3,3-dimethylbutan-2-yl]-3-pyridin-4-ylguanidine Chemical compound CC(C)(C)[C@H](C)N=C(NC#N)NC1=CC=NC=C1 IVVNZDGDKPTYHK-JTQLQIEISA-N 0.000 description 2
• DPOINJQWXDTOSF-DODZYUBVSA-N 13,14-Dihydro PGE1 Chemical compound CCCCC[C@H](O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O DPOINJQWXDTOSF-DODZYUBVSA-N 0.000 description 2
• PAPNRQCYSFBWDI-UHFFFAOYSA-N 2,5-Dimethyl-1H-pyrrole Chemical compound CC1=CC=C(C)N1 PAPNRQCYSFBWDI-UHFFFAOYSA-N 0.000 description 2
• OJVAMHKKJGICOG-UHFFFAOYSA-N 2,5-hexanedione Chemical compound CC(=O)CCC(C)=O OJVAMHKKJGICOG-UHFFFAOYSA-N 0.000 description 2
• VFZRZRDOXPRTSC-UHFFFAOYSA-N 3,5-Dimethoxybenzaldehyde Chemical compound COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 2
• OWNWMOPLKWEDCE-UHFFFAOYSA-N 3-(6-methyl-4-propylmorpholin-2-yl)phenol Chemical compound C1N(CCC)CC(C)OC1C1=CC=CC(O)=C1 OWNWMOPLKWEDCE-UHFFFAOYSA-N 0.000 description 2
• WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 2
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
• NALVGTOMKSKFFV-UHFFFAOYSA-N 4-fluoro-3-methoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC=C1F NALVGTOMKSKFFV-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
• 108060003345 Adrenergic Receptor Proteins 0.000 description 2
• 102000017910 Adrenergic receptor Human genes 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• 208000000044 Amnesia Diseases 0.000 description 2
• 208000031091 Amnestic disease Diseases 0.000 description 2
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
• 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
• 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• TVZCRIROJQEVOT-CABCVRRESA-N Cromakalim Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C#N)CCCC1=O TVZCRIROJQEVOT-CABCVRRESA-N 0.000 description 2
• 101150049660 DRD2 gene Proteins 0.000 description 2
• 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 2
• LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
• 229940087102 Dopamine D3 receptor agonist Drugs 0.000 description 2
• 101150097070 Drd3 gene Proteins 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
• 241001313288 Labia Species 0.000 description 2
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
• 108090000028 Neprilysin Proteins 0.000 description 2
• 102000003729 Neprilysin Human genes 0.000 description 2
• SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
• 102400000050 Oxytocin Human genes 0.000 description 2
• 101800000989 Oxytocin Proteins 0.000 description 2
• 101150098694 PDE5A gene Proteins 0.000 description 2
• 239000004264 Petrolatum Substances 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 229940127315 Potassium Channel Openers Drugs 0.000 description 2
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
• 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 2
• 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 2
• 102000012088 Vasoactive Intestinal Peptide Receptors Human genes 0.000 description 2
• 108010075974 Vasoactive Intestinal Peptide Receptors Proteins 0.000 description 2
• OZPWNCNLFBVVEN-RFYLDXRNSA-N [(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;[(9s,13s,14s)-13-methyl-17-oxo-9,11,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate;[(8r,9 Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1.OS(=O)(=O)OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4C=CC2=C1.C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 OZPWNCNLFBVVEN-RFYLDXRNSA-N 0.000 description 2
• GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 239000002160 alpha blocker Substances 0.000 description 2
• 229960000711 alprostadil Drugs 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
• 230000006986 amnesia Effects 0.000 description 2
• 230000001746 atrial effect Effects 0.000 description 2
• 108010006060 aviptadil Proteins 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
• ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
• 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 239000006143 cell culture medium Substances 0.000 description 2
• 230000003833 cell viability Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 150000001805 chlorine compounds Chemical class 0.000 description 2
• 229910052681 coesite Inorganic materials 0.000 description 2
• 230000019771 cognition Effects 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 229910052906 cristobalite Inorganic materials 0.000 description 2
• 239000013058 crude material Substances 0.000 description 2
• 238000005138 cryopreservation Methods 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• 238000007405 data analysis Methods 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 239000002027 dichloromethane extract Substances 0.000 description 2
• 229910001873 dinitrogen Inorganic materials 0.000 description 2
• XRKMNJXYOFSTBE-UHFFFAOYSA-N disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate Chemical compound O.O.[Na+].[Na+].[Fe+4].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].O=[N-] XRKMNJXYOFSTBE-UHFFFAOYSA-N 0.000 description 2
• 230000009429 distress Effects 0.000 description 2
• 239000002298 dopamine 3 receptor stimulating agent Substances 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 230000010491 emotional process Effects 0.000 description 2
• 230000002124 endocrine Effects 0.000 description 2
• 210000003038 endothelium Anatomy 0.000 description 2
• 238000011067 equilibration Methods 0.000 description 2
• 230000001856 erectile effect Effects 0.000 description 2
• 229960003133 ergot alkaloid Drugs 0.000 description 2
• 210000001752 female genitalia Anatomy 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 238000001640 fractional crystallisation Methods 0.000 description 2
• 230000008014 freezing Effects 0.000 description 2
• 238000007710 freezing Methods 0.000 description 2
• 239000012737 fresh medium Substances 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 229960003711 glyceryl trinitrate Drugs 0.000 description 2
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
• 239000003999 initiator Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 238000010902 jet-milling Methods 0.000 description 2
• GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 2
• 238000012417 linear regression Methods 0.000 description 2
• 229960002006 linsidomine Drugs 0.000 description 2
• UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
• 210000000260 male genitalia Anatomy 0.000 description 2
• NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
• 238000001819 mass spectrum Methods 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 229960002985 medroxyprogesterone acetate Drugs 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 239000003595 mist Substances 0.000 description 2
• 229960004027 molsidomine Drugs 0.000 description 2
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
• 239000006199 nebulizer Substances 0.000 description 2
• 230000001272 neurogenic effect Effects 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 239000002840 nitric oxide donor Substances 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 229960002748 norepinephrine Drugs 0.000 description 2
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
• 125000002524 organometallic group Chemical group 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 229910052763 palladium Inorganic materials 0.000 description 2
• XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
• 230000007310 pathophysiology Effects 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 210000004197 pelvis Anatomy 0.000 description 2
• 210000003899 penis Anatomy 0.000 description 2
• 229940066842 petrolatum Drugs 0.000 description 2
• 229960002310 pinacidil Drugs 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 230000009696 proliferative response Effects 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• 230000001107 psychogenic effect Effects 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 239000000700 radioactive tracer Substances 0.000 description 2
• 229940044601 receptor agonist Drugs 0.000 description 2
• 239000000018 receptor agonist Substances 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 230000036299 sexual function Effects 0.000 description 2
• 235000012239 silicon dioxide Nutrition 0.000 description 2
• 229910000029 sodium carbonate Inorganic materials 0.000 description 2
• 229940083618 sodium nitroprusside Drugs 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 229910052682 stishovite Inorganic materials 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000000844 transformation Methods 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• 229960003991 trazodone Drugs 0.000 description 2
• PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
• 229910052905 tridymite Inorganic materials 0.000 description 2
• 210000001215 vagina Anatomy 0.000 description 2
• 239000003071 vasodilator agent Substances 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• 230000004400 visual pathway Effects 0.000 description 2
• 210000000239 visual pathway Anatomy 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
• YBHMPNRDOVPQIN-UHFFFAOYSA-N (13E,15S)-15-Hydroxy-9-oxo-8(12),13-prostadienoic acid Natural products CCCCCC(O)C=CC1=C(CCCCCCC(O)=O)C(=O)CC1 YBHMPNRDOVPQIN-UHFFFAOYSA-N 0.000 description 1
• BGKHCLZFGPIKKU-UHFFFAOYSA-N (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dienoic acid Natural products CCCCCC(O)C=CC1C=CC(=O)C1CCCCCCC(O)=O BGKHCLZFGPIKKU-UHFFFAOYSA-N 0.000 description 1
• OBNYTSBDMKGLIN-NUHJPDEHSA-N (2s)-2-[[2-(6-aminopyridin-3-yl)-2-hydroxyethyl]-propylamino]propan-1-ol Chemical compound CCCN([C@@H](C)CO)CC(O)C1=CC=C(N)N=C1 OBNYTSBDMKGLIN-NUHJPDEHSA-N 0.000 description 1
• YSUBQYRZZFVMTL-YNDGFOBUSA-N (2s,5r,6r)-6-[[(2r)-2-[[3-[(e)-furan-2-ylmethylideneamino]-2-oxoimidazolidine-1-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)N(C1=O)CCN1\N=C\C1=CC=CO1 YSUBQYRZZFVMTL-YNDGFOBUSA-N 0.000 description 1
• XUKUURHRXDUEBC-SVBPBHIXSA-N (3s,5s)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SVBPBHIXSA-N 0.000 description 1
• FZEDGSMVRLKUOQ-UHFFFAOYSA-N (4-fluoro-3-methoxyphenyl)methanol Chemical compound COC1=CC(CO)=CC=C1F FZEDGSMVRLKUOQ-UHFFFAOYSA-N 0.000 description 1
• XOAOLHWGLYYCBQ-SFVWDYPZSA-N (5s)-2-(3-methoxyphenyl)-5-methyl-4-propylmorpholin-2-ol Chemical compound O1C[C@H](C)N(CCC)CC1(O)C1=CC=CC(OC)=C1 XOAOLHWGLYYCBQ-SFVWDYPZSA-N 0.000 description 1
• SBFGGDZPMSLDMQ-SFVWDYPZSA-N (5s)-2-(3-methoxyphenyl)-5-methyl-4-propylmorpholine Chemical compound O1C[C@H](C)N(CCC)CC1C1=CC=CC(OC)=C1 SBFGGDZPMSLDMQ-SFVWDYPZSA-N 0.000 description 1
• ONEKWEYEMWQCHS-UCFFOFKASA-N (5s)-2-[6-(2,5-dimethylpyrrol-1-yl)pyridin-3-yl]-5-methyl-4-propylmorpholin-2-ol Chemical compound O1C[C@H](C)N(CCC)CC1(O)C1=CC=C(N2C(=CC=C2C)C)N=C1 ONEKWEYEMWQCHS-UCFFOFKASA-N 0.000 description 1
• LHTRQMBCJMJKCX-ZETCQYMHSA-N (5s)-5-methyl-4-propylmorpholin-2-one Chemical compound CCCN1CC(=O)OC[C@@H]1C LHTRQMBCJMJKCX-ZETCQYMHSA-N 0.000 description 1
• XUKAVPATXGYVKJ-WPKBUWHJSA-N (6ar,9r)-n-[(2s)-1-hydroxypropan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CN(C)C3=C1 XUKAVPATXGYVKJ-WPKBUWHJSA-N 0.000 description 1
• YUSCRGFYKCAQHE-HQFNMCNFSA-N (8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;(8r,9s,13s,14s,16r,17r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 YUSCRGFYKCAQHE-HQFNMCNFSA-N 0.000 description 1
• BKMMTJMQCTUHRP-VKHMYHEASA-N (S)-2-aminopropan-1-ol Chemical compound C[C@H](N)CO BKMMTJMQCTUHRP-VKHMYHEASA-N 0.000 description 1
• PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
• FYBFDIIAPRHIQS-KKBLUXBBSA-N (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-thiophen-3-yloxybut-1-enyl]cyclopentyl]hept-5-enoic acid Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC=1C=CSC=1 FYBFDIIAPRHIQS-KKBLUXBBSA-N 0.000 description 1
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
• HCECSCMCDGLYFU-UHFFFAOYSA-N 1-(3,5-dimethoxyphenyl)-2-(propylamino)ethanol Chemical compound CCCNCC(O)C1=CC(OC)=CC(OC)=C1 HCECSCMCDGLYFU-UHFFFAOYSA-N 0.000 description 1
• YXXKQOFSTLERAJ-UHFFFAOYSA-N 1-(3-methoxyphenyl)-2-(propylamino)ethanol Chemical compound CCCNCC(O)C1=CC=CC(OC)=C1 YXXKQOFSTLERAJ-UHFFFAOYSA-N 0.000 description 1
• USTOOWLKDFWWMN-UHFFFAOYSA-N 1-(4-fluoro-3-methoxyphenyl)-2-(propylamino)ethanol Chemical compound CCCNCC(O)C1=CC=C(F)C(OC)=C1 USTOOWLKDFWWMN-UHFFFAOYSA-N 0.000 description 1
• RKEBQLVAZSZKLE-UHFFFAOYSA-N 1-(4-phenylmethoxyphenyl)-2-(propylamino)ethanol Chemical compound C1=CC(C(O)CNCCC)=CC=C1OCC1=CC=CC=C1 RKEBQLVAZSZKLE-UHFFFAOYSA-N 0.000 description 1
• UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 1
• QUUJQFQTLSFCKW-UHFFFAOYSA-N 1-[4-(1,3-benzodioxol-5-ylmethylamino)-6-chloroquinazolin-2-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=NC(NCC=2C=C3OCOC3=CC=2)=C(C=C(Cl)C=C2)C2=N1 QUUJQFQTLSFCKW-UHFFFAOYSA-N 0.000 description 1
• OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
• BRBNVIXMODBSND-UHFFFAOYSA-N 1-methyl-5-[5-(2-morpholin-4-ylacetyl)-2-propoxyphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC(=O)C=3N(C)N=C(CCC)C=3N=2)C(OCCC)=CC=C1C(=O)CN1CCOCC1 BRBNVIXMODBSND-UHFFFAOYSA-N 0.000 description 1
• NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
• GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
• PPYRMVKHPFIXEU-BAKUXOMWSA-N 19-hydroxy-PGB2 Chemical compound CC(O)CCC[C@H](O)\C=C\C1=C(C\C=C/CCCC(O)=O)C(=O)CC1 PPYRMVKHPFIXEU-BAKUXOMWSA-N 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical class C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 1
• FSKYZRCACCHDGR-UHFFFAOYSA-N 1h-pyrido[3,2-d]pyrimidin-4-one Chemical class C1=CN=C2C(=O)N=CNC2=C1 FSKYZRCACCHDGR-UHFFFAOYSA-N 0.000 description 1
• XGHBKRKXZTUREB-UHFFFAOYSA-N 2-(2,5-dimethylpyrrol-1-yl)-5-(oxiran-2-yl)pyridine Chemical compound CC1=CC=C(C)N1C1=CC=C(C2OC2)C=N1 XGHBKRKXZTUREB-UHFFFAOYSA-N 0.000 description 1
• VVUYKKHDKURKHH-UHFFFAOYSA-N 2-(3,5-dimethoxyphenyl)-4-propylmorpholine Chemical compound C1N(CCC)CCOC1C1=CC(OC)=CC(OC)=C1 VVUYKKHDKURKHH-UHFFFAOYSA-N 0.000 description 1
• WCFNRADDDOVFAG-UHFFFAOYSA-N 2-(3-bromo-4-phenylmethoxyphenyl)-4-propylmorpholine Chemical compound C1N(CCC)CCOC1C(C=C1Br)=CC=C1OCC1=CC=CC=C1 WCFNRADDDOVFAG-UHFFFAOYSA-N 0.000 description 1
• BLVMMLMFXYKMPX-UHFFFAOYSA-N 2-(3-methoxyphenyl)-4-propylmorpholine Chemical compound C1N(CCC)CCOC1C1=CC=CC(OC)=C1 BLVMMLMFXYKMPX-UHFFFAOYSA-N 0.000 description 1
• RDLVEIWWMLUWNF-UHFFFAOYSA-N 2-(3-methoxyphenyl)-6-methyl-4-propylmorpholine Chemical compound C1N(CCC)CC(C)OC1C1=CC=CC(OC)=C1 RDLVEIWWMLUWNF-UHFFFAOYSA-N 0.000 description 1
• WZGRAZZOCGLUHH-UHFFFAOYSA-N 2-(4-chloro-3-methoxyphenyl)-4-propylmorpholine Chemical compound C1N(CCC)CCOC1C1=CC=C(Cl)C(OC)=C1 WZGRAZZOCGLUHH-UHFFFAOYSA-N 0.000 description 1
• ZTAQBNKZCRIMNG-UHFFFAOYSA-N 2-(4-fluoro-3-methoxyphenyl)-4-propylmorpholine Chemical compound C1N(CCC)CCOC1C1=CC=C(F)C(OC)=C1 ZTAQBNKZCRIMNG-UHFFFAOYSA-N 0.000 description 1
• AUUDNCBDZHBKMP-UHFFFAOYSA-N 2-(4-phenylmethoxyphenyl)-4-propylmorpholine Chemical compound C1N(CCC)CCOC1C(C=C1)=CC=C1OCC1=CC=CC=C1 AUUDNCBDZHBKMP-UHFFFAOYSA-N 0.000 description 1
• YQMQTEJARSWZPZ-UHFFFAOYSA-N 2-amino-1-(3-methoxyphenyl)ethanol Chemical compound COC1=CC=CC(C(O)CN)=C1 YQMQTEJARSWZPZ-UHFFFAOYSA-N 0.000 description 1
• LBNVNODDDSSXCY-UHFFFAOYSA-N 2-amino-1-(4-chloro-3-methoxyphenyl)ethanol Chemical compound COC1=CC(C(O)CN)=CC=C1Cl LBNVNODDDSSXCY-UHFFFAOYSA-N 0.000 description 1
• RJYCTAQEHBSFSH-UHFFFAOYSA-N 2-amino-1-(4-fluoro-3-methoxyphenyl)ethanol Chemical compound COC1=CC(C(O)CN)=CC=C1F RJYCTAQEHBSFSH-UHFFFAOYSA-N 0.000 description 1
• YZOUUVUNKGUDSK-UHFFFAOYSA-N 2-amino-1-(4-phenylmethoxyphenyl)ethanol Chemical compound C1=CC(C(O)CN)=CC=C1OCC1=CC=CC=C1 YZOUUVUNKGUDSK-UHFFFAOYSA-N 0.000 description 1
• IOOHBIFQNQQUFI-UHFFFAOYSA-N 2-bromo-1-(3-methoxyphenyl)ethanone Chemical compound COC1=CC=CC(C(=O)CBr)=C1 IOOHBIFQNQQUFI-UHFFFAOYSA-N 0.000 description 1
• IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
• SCOJKGRNQDKFRP-UHFFFAOYSA-N 2-chloro-n-methoxy-n-methylacetamide Chemical compound CON(C)C(=O)CCl SCOJKGRNQDKFRP-UHFFFAOYSA-N 0.000 description 1
• XNOYVTCERVOCMV-UHFFFAOYSA-N 2-ethyl-6-(3-methoxyphenyl)-4-propylmorpholin-3-one Chemical compound O1C(CC)C(=O)N(CCC)CC1C1=CC=CC(OC)=C1 XNOYVTCERVOCMV-UHFFFAOYSA-N 0.000 description 1
• XWIFREIAHMOYEZ-UHFFFAOYSA-N 2-ethyl-6-(3-methoxyphenyl)-4-propylmorpholine Chemical compound C1N(CCC)CC(CC)OC1C1=CC=CC(OC)=C1 XWIFREIAHMOYEZ-UHFFFAOYSA-N 0.000 description 1
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• VXODQPFBRCBUSW-UHFFFAOYSA-N 2-nitro-4-(4-propylmorpholin-2-yl)phenol Chemical compound C1N(CCC)CCOC1C1=CC=C(O)C([N+]([O-])=O)=C1 VXODQPFBRCBUSW-UHFFFAOYSA-N 0.000 description 1
• LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
• PPWLAQVKIFDULF-UHFFFAOYSA-N 2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C=C1C1=CC=CC=C1 PPWLAQVKIFDULF-UHFFFAOYSA-N 0.000 description 1
• JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 1
• NARNOSPCARRMAR-UHFFFAOYSA-N 3-(6-ethyl-4-propylmorpholin-2-yl)phenol Chemical compound C1N(CCC)CC(CC)OC1C1=CC=CC(O)=C1 NARNOSPCARRMAR-UHFFFAOYSA-N 0.000 description 1
• SBHNNNRQZGYOAU-YVEFUNNKSA-N 3-[(6ar,9s)-5-bromo-7-methyl-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-yl]-1,1-diethylurea Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=C(Br)NC3=C1 SBHNNNRQZGYOAU-YVEFUNNKSA-N 0.000 description 1
• FCRJELOYDVBTGW-ILZDJORESA-N 3-[(6ar,9s,10ar)-7-propyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]-1,1-diethylurea Chemical compound C1=CC([C@H]2C[C@@H](CN([C@@H]2C2)CCC)NC(=O)N(CC)CC)=C3C2=CNC3=C1 FCRJELOYDVBTGW-ILZDJORESA-N 0.000 description 1
• ZEDCOUIRGFQKTH-UHFFFAOYSA-N 3-acetyl-1-[(2-chlorophenyl)methyl]-2-propylindole-6-carboxylic acid Chemical compound CCCC1=C(C(C)=O)C2=CC=C(C(O)=O)C=C2N1CC1=CC=CC=C1Cl ZEDCOUIRGFQKTH-UHFFFAOYSA-N 0.000 description 1
• SISGKOAGBAJWPA-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methylpropoxy)pyridin-3-yl]-2-(1-methylpiperidin-4-yl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCC(C)C)C(C=2NC(=O)C3=NN(C(CC)=C3N=2)C2CCN(C)CC2)=C1 SISGKOAGBAJWPA-UHFFFAOYSA-N 0.000 description 1
• WKISNFXGTYNPOO-OAHLLOKOSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-[(2r)-1-methoxypropan-2-yl]oxypyridin-3-yl]-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(O[C@H](C)COC)C(C=2NC(=O)C3=NN(C)C(CC)=C3N=2)=C1 WKISNFXGTYNPOO-OAHLLOKOSA-N 0.000 description 1
• NIBCDDKWFDEBEP-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=CC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC1=C2CC)=NC(=O)C1=NN2CC1=CC=CC=N1 NIBCDDKWFDEBEP-UHFFFAOYSA-N 0.000 description 1
• NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
• ZRFWHHCXSSACAW-UHFFFAOYSA-M 3-morpholin-4-yloxadiazol-3-ium-5-amine;chloride Chemical compound [Cl-].O1C(N)=C[N+](N2CCOCC2)=N1 ZRFWHHCXSSACAW-UHFFFAOYSA-M 0.000 description 1
• IZHCCKWRFAIIPH-UHFFFAOYSA-N 4-(4-propylmorpholin-2-yl)phenol Chemical compound C1N(CCC)CCOC1C1=CC=C(O)C=C1 IZHCCKWRFAIIPH-UHFFFAOYSA-N 0.000 description 1
• BMUKKTUHUDJSNZ-UHFFFAOYSA-N 4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)COC1=CC=CC=C1 BMUKKTUHUDJSNZ-UHFFFAOYSA-N 0.000 description 1
• NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
• ZVTWZSXLLMNMQC-UHFFFAOYSA-N 4-phenylmethoxybenzaldehyde Chemical compound C1=CC(C=O)=CC=C1OCC1=CC=CC=C1 ZVTWZSXLLMNMQC-UHFFFAOYSA-N 0.000 description 1
• INLBUQIADGPECI-UHFFFAOYSA-N 5-(5-acetyl-2-butoxypyridin-3-yl)-3-ethyl-2-(1-ethylazetidin-3-yl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCCOC1=NC=C(C(C)=O)C=C1C1=NC2=C(CC)N(C3CN(CC)C3)N=C2C(=O)N1 INLBUQIADGPECI-UHFFFAOYSA-N 0.000 description 1
• SUNRSIDIGUGCSU-UHFFFAOYSA-N 5-(5-acetyl-2-propoxypyridin-3-yl)-3-ethyl-2-(1-propan-2-ylazetidin-3-yl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=NC=C(C(C)=O)C=C1C1=NC2=C(CC)N(C3CN(C3)C(C)C)N=C2C(=O)N1 SUNRSIDIGUGCSU-UHFFFAOYSA-N 0.000 description 1
• 108091005477 5-HT3 receptors Proteins 0.000 description 1
• 108091005435 5-HT6 receptors Proteins 0.000 description 1
• NMEFXGPLRHHGTK-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-phenyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCOC1=NC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CC)N2C1=CC=CC=C1 NMEFXGPLRHHGTK-UHFFFAOYSA-N 0.000 description 1
• QWMFKVNJIYNWII-UHFFFAOYSA-N 5-bromo-2-(2,5-dimethylpyrrol-1-yl)pyridine Chemical compound CC1=CC=C(C)N1C1=CC=C(Br)C=N1 QWMFKVNJIYNWII-UHFFFAOYSA-N 0.000 description 1
• QPBXXHOQSFVUKL-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-2-ylmethylamino)-1h-pyridazin-6-one Chemical compound C1=CC(Cl)=CC=C1CCCOC1=NNC(=O)C(Br)=C1NCC1=CC=CC=N1 QPBXXHOQSFVUKL-UHFFFAOYSA-N 0.000 description 1
• YJMYSLFFZJUXOA-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C1=CC(Cl)=CC=C1CCCOC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 YJMYSLFFZJUXOA-UHFFFAOYSA-N 0.000 description 1
• WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 1
• PHRZFJNZFGXHQS-UHFFFAOYSA-N 6-(3,5-dimethoxyphenyl)-4-propylmorpholin-3-one Chemical compound O1CC(=O)N(CCC)CC1C1=CC(OC)=CC(OC)=C1 PHRZFJNZFGXHQS-UHFFFAOYSA-N 0.000 description 1
• CEAIARPCLHBMPG-UHFFFAOYSA-N 6-(3-methoxyphenyl)-2-methyl-4-propylmorpholin-3-one Chemical compound O1C(C)C(=O)N(CCC)CC1C1=CC=CC(OC)=C1 CEAIARPCLHBMPG-UHFFFAOYSA-N 0.000 description 1
• UMRILYSMEDJJOG-UHFFFAOYSA-N 6-(3-methoxyphenyl)-4-propylmorpholin-3-one Chemical compound O1CC(=O)N(CCC)CC1C1=CC=CC(OC)=C1 UMRILYSMEDJJOG-UHFFFAOYSA-N 0.000 description 1
• WHTKKFJNNCGJKL-UHFFFAOYSA-N 6-(4-chloro-3-methoxyphenyl)-4-propylmorpholin-3-one Chemical compound O1CC(=O)N(CCC)CC1C1=CC=C(Cl)C(OC)=C1 WHTKKFJNNCGJKL-UHFFFAOYSA-N 0.000 description 1
• IVJMNLODVNTXFE-UHFFFAOYSA-N 6-(4-fluoro-3-methoxyphenyl)-4-propylmorpholin-3-one Chemical compound O1CC(=O)N(CCC)CC1C1=CC=C(F)C(OC)=C1 IVJMNLODVNTXFE-UHFFFAOYSA-N 0.000 description 1
• VCCNKWWXYVWTLT-CYZBKYQRSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCCNKWWXYVWTLT-CYZBKYQRSA-N 0.000 description 1
• 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 206010002261 Androgen deficiency Diseases 0.000 description 1
• 206010002652 Anorgasmia Diseases 0.000 description 1
• 206010003439 Artificial menopause Diseases 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 102100036465 Autoimmune regulator Human genes 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 239000002083 C09CA01 - Losartan Substances 0.000 description 1
• 101100135858 Caenorhabditis elegans pde-2 gene Proteins 0.000 description 1
• 101100135867 Caenorhabditis elegans pde-3 gene Proteins 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
• 108050007331 Cannabinoid receptor Proteins 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 108091006146 Channels Proteins 0.000 description 1
• 108010023798 Charybdotoxin Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
• 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
• 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
• 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 description 1
• 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
• 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
• 208000004483 Dyspareunia Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 108010059378 Endopeptidases Proteins 0.000 description 1
• 102000005593 Endopeptidases Human genes 0.000 description 1
• 102000010180 Endothelin receptor Human genes 0.000 description 1
• 108050001739 Endothelin receptor Proteins 0.000 description 1
• 241001492222 Epicoccum Species 0.000 description 1
• IHPHPGLJYCDONF-UHFFFAOYSA-N Essigsaeure-propylamid Natural products CCCNC(C)=O IHPHPGLJYCDONF-UHFFFAOYSA-N 0.000 description 1
• 241000400611 Eucalyptus deanei Species 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 101150104779 HTR2A gene Proteins 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 102000007625 Hirudins Human genes 0.000 description 1
• 108010007267 Hirudins Proteins 0.000 description 1
• 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 description 1
• 101000865224 Homo sapiens D(3) dopamine receptor Proteins 0.000 description 1
• 101150013372 Htr2c gene Proteins 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 206010020850 Hyperthyroidism Diseases 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 229940122355 Insulin sensitizer Drugs 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 229940117029 Melanocortin receptor agonist Drugs 0.000 description 1
• 108010008364 Melanocortins Proteins 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
• FQWRAVYMZULPNK-UHFFFAOYSA-N N(5)-[(Z)-amino(hydroxyimino)methyl]ornithine Chemical compound OC(=O)C(N)CCCNC(N)=NO FQWRAVYMZULPNK-UHFFFAOYSA-N 0.000 description 1
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• HRRBJVNMSRJFHQ-UHFFFAOYSA-N Naftopidil Chemical compound COC1=CC=CC=C1N1CCN(CC(O)COC=2C3=CC=CC=C3C=CC=2)CC1 HRRBJVNMSRJFHQ-UHFFFAOYSA-N 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 101710138657 Neurotoxin Proteins 0.000 description 1
• YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 239000000006 Nitroglycerin Substances 0.000 description 1
• 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
• 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
• 229940121954 Opioid receptor agonist Drugs 0.000 description 1
• 229940123257 Opioid receptor antagonist Drugs 0.000 description 1
• 102000004279 Oxytocin receptors Human genes 0.000 description 1
• 108090000876 Oxytocin receptors Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 244000131316 Panax pseudoginseng Species 0.000 description 1
• 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
• 235000003140 Panax quinquefolius Nutrition 0.000 description 1
• 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
• TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
• 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
• QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• 229940121828 Phosphodiesterase 2 inhibitor Drugs 0.000 description 1
• 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
• 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 description 1
• 208000005374 Poisoning Diseases 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
• 102000003946 Prolactin Human genes 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
• 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 description 1
• 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
• 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
• 239000004147 Sorbitan trioleate Substances 0.000 description 1
• PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
• 208000029033 Spinal Cord disease Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 239000000219 Sympatholytic Substances 0.000 description 1
• DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
• JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 229940122388 Thrombin inhibitor Drugs 0.000 description 1
• 102100038388 Vasoactive intestinal polypeptide receptor 1 Human genes 0.000 description 1
• 101710137655 Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 description 1
• 102000004136 Vasopressin Receptors Human genes 0.000 description 1
• 108090000643 Vasopressin Receptors Proteins 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• MMPCMJGFURZYOY-WRWLIDTKSA-N [(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methyl azepane-1-carboxylate Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)OC(=O)N1CCCCCC1 MMPCMJGFURZYOY-WRWLIDTKSA-N 0.000 description 1
• TZHYBRCGYCPGBQ-UHFFFAOYSA-N [B].[N] Chemical compound [B].[N] TZHYBRCGYCPGBQ-UHFFFAOYSA-N 0.000 description 1
• RQBGLYREDLMZMC-UHFFFAOYSA-N [N].C1COCCN1 Chemical compound [N].C1COCCN1 RQBGLYREDLMZMC-UHFFFAOYSA-N 0.000 description 1
• ANZIISNSHPKVRV-UHFFFAOYSA-N abanoquil Chemical compound C1=C(OC)C(OC)=CC2=NC(N3CCC=4C=C(C(=CC=4C3)OC)OC)=CC(N)=C21 ANZIISNSHPKVRV-UHFFFAOYSA-N 0.000 description 1
• 229950010137 abanoquil Drugs 0.000 description 1
• 230000009102 absorption Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• VPXSOMITANBBPE-XGWLTEMNSA-N acetergamine Chemical compound C1=CC=C2[C@H]3C[C@@H](CNC(C)=O)CN(C)[C@@H]3CC3=CN=C1[C]32 VPXSOMITANBBPE-XGWLTEMNSA-N 0.000 description 1
• 229950004701 acetergamine Drugs 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 239000000674 adrenergic antagonist Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000008484 agonism Effects 0.000 description 1
• 229960004607 alfuzosin Drugs 0.000 description 1
• WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
• 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
• 102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 1
• 108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 1
• 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
• 239000004411 aluminium Substances 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
• 229960000528 amlodipine Drugs 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• HSNWZBCBUUSSQD-UHFFFAOYSA-N amyl nitrate Chemical compound CCCCCO[N+]([O-])=O HSNWZBCBUUSSQD-UHFFFAOYSA-N 0.000 description 1
• 210000003484 anatomy Anatomy 0.000 description 1
• 229960003473 androstanolone Drugs 0.000 description 1
• 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
• 230000003276 anti-hypertensive effect Effects 0.000 description 1
• 230000000702 anti-platelet effect Effects 0.000 description 1
• 239000003529 anticholesteremic agent Substances 0.000 description 1
• 229940127226 anticholesterol agent Drugs 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 239000003472 antidiabetic agent Substances 0.000 description 1
• 239000000739 antihistaminic agent Substances 0.000 description 1
• 229940125715 antihistaminic agent Drugs 0.000 description 1
• 229940030600 antihypertensive agent Drugs 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940127218 antiplatelet drug Drugs 0.000 description 1
• 239000003420 antiserotonin agent Substances 0.000 description 1
• 229960004676 antithrombotic agent Drugs 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 230000001623 arteriogenic effect Effects 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• SHZPNDRIDUBNMH-NIJVSVLQSA-L atorvastatin calcium trihydrate Chemical compound O.O.O.[Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 SHZPNDRIDUBNMH-NIJVSVLQSA-L 0.000 description 1
• 229950000586 aviptadil Drugs 0.000 description 1
• 238000010533 azeotropic distillation Methods 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 230000036471 bradycardia Effects 0.000 description 1
• 208000006218 bradycardia Diseases 0.000 description 1
• 229950010062 brazergoline Drugs 0.000 description 1
• FFHBJDQSGDNCIV-MFVUMRCOSA-N bremelanotide Chemical compound C([C@@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCNC(=O)C[C@@H](C(N[C@@H](CC=2NC=NC=2)C(=O)N1)=O)NC(=O)[C@@H](NC(C)=O)CCCC)C(O)=O)C1=CC=CC=C1 FFHBJDQSGDNCIV-MFVUMRCOSA-N 0.000 description 1
• 229950006651 bromerguride Drugs 0.000 description 1
• 230000031709 bromination Effects 0.000 description 1
• 238000005893 bromination reaction Methods 0.000 description 1
• 230000005587 bubbling Effects 0.000 description 1
• SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
• 229960001058 bupropion Drugs 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 1
• 229960004205 carbidopa Drugs 0.000 description 1
• 125000004432 carbon atom Chemical group C* 0.000 description 1
• UMMADZJLZAPZAW-OVXHCKHTSA-N carboprost tromethamine Chemical compound OCC([NH3+])(CO)CO.CCCCC[C@](C)(O)\C=C\[C@H]1[C@@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC([O-])=O UMMADZJLZAPZAW-OVXHCKHTSA-N 0.000 description 1
• 229960005296 carboprost tromethamine Drugs 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229940062399 cenestin Drugs 0.000 description 1
• 229940081733 cetearyl alcohol Drugs 0.000 description 1
• 230000035606 childbirth Effects 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 238000004296 chiral HPLC Methods 0.000 description 1
• 239000000544 cholinesterase inhibitor Substances 0.000 description 1
• 235000019504 cigarettes Nutrition 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• DYIUKMSMAJWWAT-NEPJUHHUSA-N cis-2-hexyl-5-methyl-3,4,5,6a,7,8,9,9a-octahydrocyclopent[4,5]-imidazo[2, 1-b]purin-4-one Chemical compound N([C@@H]1CCC[C@@H]1N12)=C1N(C)C(=O)C1=C2NC(CCCCCC)=N1 DYIUKMSMAJWWAT-NEPJUHHUSA-N 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 229960002896 clonidine Drugs 0.000 description 1
• 208000018912 cluster headache syndrome Diseases 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 230000000056 copulatory effect Effects 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 229960001681 croscarmellose sodium Drugs 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 238000002447 crystallographic data Methods 0.000 description 1
• CNVQLPPZGABUCM-LIGYZCPXSA-N ctx toxin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@@H](C(N[C@@H](CC=4C5=CC=CC=C5NC=4)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3NC=NC=3)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N2)C(C)C)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC1=O)=O)CCSC)C(C)C)[C@@H](C)O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 CNVQLPPZGABUCM-LIGYZCPXSA-N 0.000 description 1
• 238000009109 curative therapy Methods 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 229960000729 cyclandelate Drugs 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 229960002947 dapiprazole Drugs 0.000 description 1
• RFWZESUMWJKKRN-UHFFFAOYSA-N dapiprazole Chemical compound CC1=CC=CC=C1N1CCN(CCC=2N3CCCCC3=NN=2)CC1 RFWZESUMWJKKRN-UHFFFAOYSA-N 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• KWDSFGYQALRPMG-UHFFFAOYSA-N delta-N-Hydroxy-L-orginin Natural products OC(=O)C(N)CCCN(O)C(N)=N KWDSFGYQALRPMG-UHFFFAOYSA-N 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 229960003914 desipramine Drugs 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• RAABOESOVLLHRU-UHFFFAOYSA-O diazenium Chemical compound [NH2+]=N RAABOESOVLLHRU-UHFFFAOYSA-O 0.000 description 1
• 235000019700 dicalcium phosphate Nutrition 0.000 description 1
• 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
• UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
• 229940099364 dichlorofluoromethane Drugs 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• 229960001342 dinoprost Drugs 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
• 230000003291 dopaminomimetic effect Effects 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 229960001389 doxazosin Drugs 0.000 description 1
• RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 229940126534 drug product Drugs 0.000 description 1
• 229940112141 dry powder inhaler Drugs 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 230000002996 emotional effect Effects 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000008387 emulsifying waxe Substances 0.000 description 1
• OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• YREISLCRUMOYAY-IIPCNOPRSA-N ergometrine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 YREISLCRUMOYAY-IIPCNOPRSA-N 0.000 description 1
• 229940030804 ergonovine maleate Drugs 0.000 description 1
• 229960001903 ergotamine tartrate Drugs 0.000 description 1
• SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229940064258 estrace Drugs 0.000 description 1
• 229940098618 estring Drugs 0.000 description 1
• 239000000328 estrogen antagonist Substances 0.000 description 1
• 239000002834 estrogen receptor modulator Substances 0.000 description 1
• JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 229960004979 fampridine Drugs 0.000 description 1
• 229940125753 fibrate Drugs 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 238000011990 functional testing Methods 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• KYBOHGVERHWSSV-VNIVIJDLSA-N gemeprost Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC KYBOHGVERHWSSV-VNIVIJDLSA-N 0.000 description 1
• 229960003480 gemeprost Drugs 0.000 description 1
• 235000008434 ginseng Nutrition 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 229960004580 glibenclamide Drugs 0.000 description 1
• ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
• 229960001381 glipizide Drugs 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
• 229940049654 glyceryl behenate Drugs 0.000 description 1
• 230000002710 gonadal effect Effects 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 229960003878 haloperidol Drugs 0.000 description 1
• XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
• 230000000004 hemodynamic effect Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
• 229940006607 hirudin Drugs 0.000 description 1
• WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 150000004678 hydrides Chemical class 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 229940126904 hypoglycaemic agent Drugs 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 230000002267 hypothalamic effect Effects 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 229950001476 idazoxan Drugs 0.000 description 1
• HPMRFMKYPGXPEP-UHFFFAOYSA-N idazoxan Chemical compound N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 229960002056 indoramin Drugs 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000030214 innervation Effects 0.000 description 1
• 239000013067 intermediate product Substances 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 108010024941 iodothyronine deiodinase type II Proteins 0.000 description 1
• MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
• 229960000201 isosorbide dinitrate Drugs 0.000 description 1
• YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
• 229960003827 isosorbide mononitrate Drugs 0.000 description 1
• 229960004819 isoxsuprine Drugs 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• PRFXRIUZNKLRHM-UHFFFAOYSA-N l-prostaglandin B2 Natural products CCCCCC(O)C=CC1=C(CC=CCCCC(O)=O)C(=O)CC1 PRFXRIUZNKLRHM-UHFFFAOYSA-N 0.000 description 1
• 230000006651 lactation Effects 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 230000001983 lactogenic effect Effects 0.000 description 1
• 229960002367 lasofoxifene Drugs 0.000 description 1
• 235000005772 leucine Nutrition 0.000 description 1
• FKDHHVKWGRFRTG-UHFFFAOYSA-N linsidomine Chemical compound [N-]1OC(=N)C=[N+]1N1CCOCC1 FKDHHVKWGRFRTG-UHFFFAOYSA-N 0.000 description 1
• 229940002661 lipitor Drugs 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 230000006742 locomotor activity Effects 0.000 description 1
• KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
• 229960004773 losartan Drugs 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 229950002454 lysergide Drugs 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 229960004616 medroxyprogesterone Drugs 0.000 description 1
• 239000002865 melanocortin Substances 0.000 description 1
• 239000000336 melanocortin receptor agonist Substances 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
• 229960004650 metergoline Drugs 0.000 description 1
• SZUQJDJBJHBVBO-CTTKVJGISA-N metergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4N(C)C=C(C=34)C2)=C1)C)C1=CC=CC=C1 SZUQJDJBJHBVBO-CTTKVJGISA-N 0.000 description 1
• 229950004958 metergotamine Drugs 0.000 description 1
• IYUKFAFDFHZKPI-DFWYDOINSA-N methyl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](C)N IYUKFAFDFHZKPI-DFWYDOINSA-N 0.000 description 1
• YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
• MXELDPKESKXREN-UHFFFAOYSA-N methyl 5-[3-(4,4-diphenylpiperidin-1-yl)propylcarbamoyl]-2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(CC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=C([N+]([O-])=O)C=C1 MXELDPKESKXREN-UHFFFAOYSA-N 0.000 description 1
• 150000004702 methyl esters Chemical class 0.000 description 1
• 229960001566 methyltestosterone Drugs 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 229960003632 minoxidil Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 239000002808 molecular sieve Substances 0.000 description 1
• XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 229950005705 naftopidil Drugs 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 239000002581 neurotoxin Substances 0.000 description 1
• 231100000618 neurotoxin Toxicity 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 229960003642 nicergoline Drugs 0.000 description 1
• 229960002497 nicorandil Drugs 0.000 description 1
• LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 229960003753 nitric oxide Drugs 0.000 description 1
• 150000002828 nitro derivatives Chemical class 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
• LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
• 108010020615 nociceptin receptor Proteins 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 230000001129 nonadrenergic effect Effects 0.000 description 1
• 230000002536 noncholinergic effect Effects 0.000 description 1
• 230000002474 noradrenergic effect Effects 0.000 description 1
• 210000001009 nucleus accumben Anatomy 0.000 description 1
• 210000000869 occipital lobe Anatomy 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
• 229950000973 omapatrilat Drugs 0.000 description 1
• 239000003402 opiate agonist Substances 0.000 description 1
• 239000003401 opiate antagonist Substances 0.000 description 1
• 210000001328 optic nerve Anatomy 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 239000003539 oral contraceptive agent Substances 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 125000001979 organolithium group Chemical group 0.000 description 1
• 125000002734 organomagnesium group Chemical group 0.000 description 1
• 208000015124 ovarian disease Diseases 0.000 description 1
• 201000004535 ovarian dysfunction Diseases 0.000 description 1
• 231100000543 ovarian dysfunction Toxicity 0.000 description 1
• 210000003101 oviduct Anatomy 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 230000003049 oxytocinergic effect Effects 0.000 description 1
• PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
• 238000002638 palliative care Methods 0.000 description 1
• 229960001789 papaverine Drugs 0.000 description 1
• 229960003207 papaverine hydrochloride Drugs 0.000 description 1
• 230000001734 parasympathetic effect Effects 0.000 description 1
• 210000002963 paraventricular hypothalamic nucleus Anatomy 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
• 229960004851 pergolide Drugs 0.000 description 1
• YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 208000027232 peripheral nervous system disease Diseases 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229960003418 phenoxybenzamine Drugs 0.000 description 1
• 229960001999 phentolamine Drugs 0.000 description 1
• MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
• 229960003056 phentolamine mesylate Drugs 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
• 231100000572 poisoning Toxicity 0.000 description 1
• 230000000607 poisoning effect Effects 0.000 description 1
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
• 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
• 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
• 229940113124 polysorbate 60 Drugs 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 238000011176 pooling Methods 0.000 description 1
• 230000001242 postsynaptic effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229960001289 prazosin Drugs 0.000 description 1
• IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 229940063238 premarin Drugs 0.000 description 1
• 206010036601 premature menopause Diseases 0.000 description 1
• 208000017942 premature ovarian failure 1 Diseases 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000000436 pro-erectile effect Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
• 229940080818 propionamide Drugs 0.000 description 1
• 229950004866 propisergide Drugs 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• BGKHCLZFGPIKKU-LDDQNKHRSA-N prostaglandin A1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(O)=O BGKHCLZFGPIKKU-LDDQNKHRSA-N 0.000 description 1
• YBHMPNRDOVPQIN-VSOYFRJCSA-N prostaglandin B1 Chemical compound CCCCC[C@H](O)\C=C\C1=C(CCCCCCC(O)=O)C(=O)CC1 YBHMPNRDOVPQIN-VSOYFRJCSA-N 0.000 description 1
• PRFXRIUZNKLRHM-HKVRTXJWSA-N prostaglandin B2 Chemical compound CCCCC[C@H](O)\C=C\C1=C(C\C=C/CCCC(O)=O)C(=O)CC1 PRFXRIUZNKLRHM-HKVRTXJWSA-N 0.000 description 1
• PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 235000018102 proteins Nutrition 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• 229950007140 proterguride Drugs 0.000 description 1
• 210000003689 pubic bone Anatomy 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000010298 pulverizing process Methods 0.000 description 1
• 239000013014 purified material Substances 0.000 description 1
• UYLWKSJTHLRFBX-UHFFFAOYSA-N purin-6-one Chemical class O=C1N=CN=C2N=CN=C12 UYLWKSJTHLRFBX-UHFFFAOYSA-N 0.000 description 1
• 239000003227 purinergic agonist Substances 0.000 description 1
• 210000002637 putamen Anatomy 0.000 description 1
• IUYQIJQHYDZUDF-UHFFFAOYSA-N pyrazolo[3,4-d]pyrimidin-4-one Chemical class O=C1N=CN=C2N=NC=C12 IUYQIJQHYDZUDF-UHFFFAOYSA-N 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 238000006268 reductive amination reaction Methods 0.000 description 1
• 230000002040 relaxant effect Effects 0.000 description 1
• 230000004648 relaxation of smooth muscle Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• JOSMPBVYYKRYLG-OLZOCXBDSA-N sch-51866 Chemical compound N1([C@H]2CCC[C@H]2N=C1N(C(C=1N2)=O)C)C=1N=C2CC1=CC=C(C(F)(F)F)C=C1 JOSMPBVYYKRYLG-OLZOCXBDSA-N 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 229940125723 sedative agent Drugs 0.000 description 1
• 239000000932 sedative agent Substances 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 239000000952 serotonin receptor agonist Substances 0.000 description 1
• 230000035936 sexual power Effects 0.000 description 1
• 230000036332 sexual response Effects 0.000 description 1
• 229960003310 sildenafil Drugs 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• 230000016160 smooth muscle contraction Effects 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
• 229940080313 sodium starch Drugs 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
• WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 239000001587 sorbitan monostearate Substances 0.000 description 1
• 235000011076 sorbitan monostearate Nutrition 0.000 description 1
• 229940035048 sorbitan monostearate Drugs 0.000 description 1
• 235000019337 sorbitan trioleate Nutrition 0.000 description 1
• 229960000391 sorbitan trioleate Drugs 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1
• 238000001694 spray drying Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
• 230000003637 steroidlike Effects 0.000 description 1
• 239000012258 stirred mixture Substances 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 229910021653 sulphate ion Inorganic materials 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 206010042772 syncope Diseases 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 229960002613 tamsulosin Drugs 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 229960001693 terazosin Drugs 0.000 description 1
• VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
• 229960004558 terguride Drugs 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 239000003868 thrombin inhibitor Substances 0.000 description 1
• DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
• 229950002099 tiaprost Drugs 0.000 description 1
• 229960002312 tolazoline Drugs 0.000 description 1
• JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 230000008736 traumatic injury Effects 0.000 description 1
• 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
• YNZXWQJZEDLQEG-UHFFFAOYSA-N trimazosin Chemical compound N1=C2C(OC)=C(OC)C(OC)=CC2=C(N)N=C1N1CCN(C(=O)OCC(C)(C)O)CC1 YNZXWQJZEDLQEG-UHFFFAOYSA-N 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
• 229960001641 troglitazone Drugs 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 210000001635 urinary tract Anatomy 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 206010046947 vaginismus Diseases 0.000 description 1
• 229960002381 vardenafil Drugs 0.000 description 1
• 230000004865 vascular response Effects 0.000 description 1
• 230000002227 vasoactive effect Effects 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 230000000982 vasogenic effect Effects 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 230000001720 vestibular Effects 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 230000004393 visual impairment Effects 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 229960005080 warfarin Drugs 0.000 description 1
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000003871 white petrolatum Substances 0.000 description 1
• BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
• 229960000317 yohimbine Drugs 0.000 description 1
• AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1